# US 2016/0250304 A1 · Carbapenemases for use with antibiotics for the protection of the intestinal microbiome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250304 A1
- Document ID: US20160250304A1
- Status: Published application
- Kind: A1
- Application number: 15/051,187
- Filed: 2016-02-23
- Published: 2016-09-01
- Earliest claimed: 2015-02-23
- Assignees: Synthetic Biologics, Inc.
- Applicants: Synthetic Biologics, Inc.
- Inventors: Michael Kaleko; Sheila Connelly
- Web page: https://patentgrep.com/patent/US20160250304A1

## CPC

- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/86: acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5078: {with drug-free core}
- C12Y 305/02006: Beta-lactamase (3.5.2.6)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

## Claims

### Claim 1

A method of protecting a subject's gastrointestinal microbiome, comprising administering an effective amount of a pharmaceutical composition comprising a broad spectrum carbapenemase to a subject in need thereof, wherein:
the subject is undergoing treatment or has recently undergone treatment with a carbapenem antibiotic, and
the broad spectrum carbapenemase is capable of degrading or inactivating the carbapenem in the subject's gastrointestinal tract.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the broad spectrum carbapenemase is a metallo-β-lactamase.

### Claim at position 4

-6. (canceled)

### Claim 7 (depends on 3)

The method of claim 3, wherein the broad spectrum carbapenemase has an amino acid sequence having at least 95% sequence similarity with SEQ ID NO: [37] 68.

### Claim 8 (depends on 7)

The method of claim 7, wherein the broad spectrum carbapenemase has an amino acid sequence having at least 99% sequence similarity with SEQ ID NO: 68.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the protection of the subject's microbiome comprises treatment or prevention of a microbiome-mediated disorder.

### Claim 11

(canceled)

### Claim 12

The method of claim [1] 10, wherein the microbiome-mediated disorder is one or more of an antibiotic-induced adverse effect, C. difficile infection (CDI), and a C. difficile-associated disease.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antibiotic-induced adverse effect and/or CDI or C. difficile-associated disease is one or more of: antibiotic-associated diarrhea, C. difficile diarrhea (CDD), C. difficile intestinal inflammatory disease, colitis, and pseudomembranous colitis.

### Claim 14 (depends on 1)

The method of claim 1, wherein the protection of the subject's microbiome comprises maintenance of a normal intestinal microbiota.

### Claim 15 (depends on 14)

The method of claim 14, wherein the method treats and/or prevents the overgrowth of one or more pathogenic microorganisms in the GI tract of a subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein the method treats or prevents a nosocomial infection and/or a secondary emergent infection.

### Claim 17 (depends on 1)

The method of claim 1, wherein the broad spectrum carbapenemase does not substantially interfere with blood or plasma levels of the antibiotic.

### Claim 18 (depends on 1)

The method of claim 1, wherein the broad spectrum carbapenemase degrades or inactivates excess or residual antibiotic in the subject's gastrointestinal tract.

### Claim at position 17

19-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the carbapenem is selected from meropenem, imipenem, ertapenem, and doripenem.

### Claim at position 19

23-60. (canceled)

### Claim 61

A method for producing an antibiotic-degrading agent in Escherichia coli (E. coli), comprising:
(a) providing a host E. coli cell transformed with a vector comprising a sequence encoding the antibiotic-degrading agent;
(b) culturing the E. coli cell to induce expression of the antibiotic-degrading agent; and
(c) recovering the antibiotic-degrading agent from a soluble fraction prepared from the E. coli cell,
wherein:
the antibiotic-degrading agent is broad spectrum carbapenemase having at least 95% sequence identity with the amino acid sequences of SEQ ID NO: 68 or SEQ ID NO: 53 and
the culturing is in the presence of an amount of zinc sufficient to substantially increase the amount of antibiotic-degrading agent protein in a soluble fraction and reduce the amount of antibiotic-degrading agent protein in inclusion bodies relative to culturing in the absence of zinc.

### Claim at position 21

62-76. (canceled)

### Claim 77 (depends on 61)

The method of claim 61, wherein the broad spectrum carbapenemase has an amino acid sequence of SEQ ID NO: 68.

### Claim 78 (depends on 61)

The method of claim 61, wherein the broad spectrum carbapenemase has an amino acid sequence of SEQ ID NO: 53.

### Claim 79 (depends on 8)

The method of claim 8, wherein the broad spectrum carbapenemase has an amino acid sequence having at least 99% sequence similarity with SEQ ID NO: 68 and lacks a leader sequence.

### Claim 79 (depends on 79)

The method of claim 79, wherein the broad spectrum carbapenemase consists essentially of an amino acid sequence of SEQ ID NO: 68.

### Claim 80 (depends on 1)

The method of claim 1, wherein the broad spectrum carbapenemase has an amino acid sequence having at least 95% sequence similarity with one of SEQ ID NOs: 53 and 54.

### Claim 81 (depends on 1)

The method of claim 1, wherein the broad spectrum carbapenemase has an amino acid sequence having at least 95% sequence similarity with SEQ ID NO: 38.
